Results 1 to 10 of about 2,881,820 (183)

Primary cytoreductive surgery or interval cytoreductive surgery

Taiwanese Journal of Obstetrics & Gynecology
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
doaj   +4 more sources

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

World Journal of Surgical Oncology, 2022
Background Cytoreductive surgery followed by systemic chemotherapy is the standard of treatment in advanced ovarian cancer where feasible. Neoadjuvant chemotherapy (NACT) followed by surgery is applicable where upfront cytoreductive surgery is not ...
Ester Miralpeix, Josep-Maria Sole-Sedeno, Cristina Rodriguez-Cosmen, Alvaro Taus, Maria-Dolors Muns, Berta Fabregó, Gemma Mancebo   +6 more
doaj   +2 more sources

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Frontiers in Oncology, 2022
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in
Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou   +2 more
doaj   +2 more sources

Case Report: Thoracoscopic secondary cytoreductive surgery for high-grade serous ovarian cancer [PDF]

Frontiers in Surgery
The objective of this video is to show the feasibility of secondary cytoreductive surgery for recurrent high-grade serous ovarian cancer. The procedure targets recurrences in the cardiophrenic lymph nodes and the right diaphragm involving the right basal
Luigi Carlo Turco, Benedetta Alberghetti, Carlotta Francesca Cartia, Antonella Biscione, Giacomo Guidi, Giacomo Guidi, Filippo Maria Capomacchia, Andrea Droghetti   +7 more
doaj   +2 more sources

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic ...
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. De forges, J. Paineau, O. Glehen   +16 more
semanticscholar   +1 more source

Comparison of Cytoreductive Surgery and Resection of Isolated Peritoneal Metastases in Patients with Peritoneal Metastases from Colorectal Cancer: A Retrospective Study

Journal of the Anus, Rectum and Colon, 2023
Objectives: This study aimed to compare the short and long-term outcomes of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and resection of isolated peritoneal metastases in patients with peritoneal metastases from colorectal cancer
Shinya Yoshida, Yasuyuki Kamada, Koya Hida, Kazuyuki Okada, Kazutaka Obama, Satoshi Morita, Toshiyuki Kitai, Yutaka Yonemura   +7 more
doaj   +1 more source

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study [PDF]

Obstetrics & Gynecology Science, 2020
ObjectiveThe primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine the perioperative
Semiramis L. Carbajal-Mamani, David Schweer, Merry J. Markham, Ashwini K. Esnakula, Joseph R. Grajo, Jacqueline C. Castagno, Joel Cardenas-Goicoechea   +6 more
doaj   +1 more source

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Journal of Clinical Oncology, 2023
PURPOSE In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled,
B. Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, H. Rau, H. Seeliger, C. Lerchenmueller, D. Reim, Roger Wahba, Martin Angele, S. Heeg, Tobias Keck, A. Weimann, S. Topp, P. Piso, A. Brandl, Silke Schuele, Peter Jo, J. Pratschke, S. Wegel, A. Rehders, N. Moosmann, J. Gaedcke, Volker Heinemann, E. Trips, Markus Loeffler, P. Schlag, P. Thuss-Patience   +27 more
semanticscholar   +1 more source

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone
S. Aronson, M. Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, M. V. van Gent, H. Arts, M. van Ham, P. V. van Dam, P. Vuylsteke, A. Aalbers, V. Verwaal, K. K. van de Vijver, N. Aaronson, G. Sonke, W. V. van Driel   +17 more
semanticscholar   +1 more source

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

JAMA Surgery, 2022
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer?
M. Lim, Suk-Joon Chang, Boram Park, H. Yoo, C. Yoo, B. Nam, Sang-Yoon Park   +6 more
semanticscholar   +1 more source